Clinical trial Recruiting at 1 site Interventional Ages 40 to 80

Using muscle fiber fragments to enhance rotator cuff recovery

Official title: Safety of Autologous Muscle Fiber Fragments for Improved Function of Rotator Cuff Musculature Following Rotator Cuff Repair

Run by Wake Forest University Health Sciences · NCT03752034 · Data updated 2026-11-12

This study is testing whether injecting muscle fiber fragments from the chest into the shoulder can help people recover better and regain strength after rotator cuff surgery.

More Rotator Cuff Tears trials

Quick facts

Study typeInterventional
Ages40 Years to 80 Years
SexAll
Enrollment20 (estimated)
SponsorWake Forest University Health Sciences
Academic / other
Locations1 site (Winston-Salem, North Carolina)
StatusRecruiting
StartedNovember 4, 2019
Main results expectedDecember 2026
Study endsDecember 2027
Registry record updatedMarch 27, 2026
Trial IDNCT03752034 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are males and females aged 40 to 80 with a unilateral rotator cuff tear less than 1.5 cm.

Probably not a fit

Patients with diabetes, previous shoulder surgery, or major comorbidities may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study involves taking a biopsy of chest muscle to extract muscle fiber fragments, which are then injected into the supraspinatus muscle following rotator cuff repair. The hypothesis is that these fragments will integrate into the existing muscle tissue, potentially increasing muscle size and strength, thereby improving rotator cuff function. The approach aims to provide a less invasive alternative to traditional surgical therapies, with the goal of enhancing recovery and restoring muscle function more effectively.

Why it matters

Potential benefit: If successful, this treatment could significantly improve recovery outcomes for patients undergoing rotator cuff repair.

How similar studies have gone: While muscle fiber fragment therapy has shown promise in other conditions, this specific application for rotator cuff repair is novel and has not been extensively tested.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Males and females, ages 40 to 80 years
* Unilateral Disease
* \< 1.5cm tear

Exclusion Criteria:

* Diabetes
* Peripheral Neuropathy
* Previous Shoulder Surgery
* Pain Syndrome; cuff arthroplasty
* Major co-morbidities including, but not limited to, uncontrolled diabetes, cardiovascular, pulmonary, GI, coagulopathies
* Arthritis of Shoulder
* Unwilling or unable to comply with post-operative instructions or follow-up visits
* Auto Immune Disease
* Complete Subscapularis Tear
* Teres Minor involvement
* History of testing positive for HIV, Hep B, Hep C, HTLV-1, HTLV-2
* Pregnancy
* Implanted devices containing ferromagnetic material
* Any implanted electrical stimulation devices (i.e. cochlear implant, defibrillator)
* Any other condition which the PI feels would be not in the best interest for the patient or the study

Where it's running

  • Wake Forest University Health Sciences
    Winston-Salem, North Carolina, United States
    Recruiting

Study contacts

  • Principal investigator: Gary G Poehling, MD — Wake Forest University Health Sciences
  • Study coordinator: Mary-Clare Day, RN
  • Email: mday@wakehealth.edu
  • Phone: 336-713-1343

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.